MCID: SRC014
MIFTS: 66

Sarcoma

Categories: Cancer diseases, Bone diseases

Aliases & Classifications for Sarcoma

MalaCards integrated aliases for Sarcoma:

Name: Sarcoma 12 29 52 14 69
Connective and Soft Tissue Neoplasm 12
Tumor of Soft Tissue and Skeleton 12
Sarcoma - Category 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1115
ICD10 33 C49
ICD9CM 35 171 171.9
SNOMED-CT 64 187985009 93765001
UMLS 69 C0153519

Summaries for Sarcoma

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Sarcoma, also known as connective and soft tissue neoplasm, is related to epithelioid cell synovial sarcoma and mediastinum rhabdomyosarcoma. An important gene associated with Sarcoma is SRC (SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase), and among its related pathways/superpathways are Developmental Biology and Cytokine Signaling in Immune system. The drugs Doxil and Fusilev have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and lung, and related phenotypes are Decreased viability and growth/size/body region

Wikipedia : 72 A sarcoma (plural sarcomas or sarcomata; from the Greek σάρξ sarx meaning \"flesh\") is a cancer that... more...

Related Diseases for Sarcoma

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 828)
id Related Disease Score Top Affiliating Genes
1 epithelioid cell synovial sarcoma 33.7 KIT SS18 SSX1 SSX2
2 mediastinum rhabdomyosarcoma 31.7 ASPSCR1 CREB3L2 EWSR1 KIT
3 sertoli-leydig cell tumor 29.8 BRAF HRAS KIT KRAS RB1
4 kaposi sarcoma 12.5
5 ewing sarcoma 12.3
6 follicular dendritic cell sarcoma 12.2
7 myeloid sarcoma 12.2
8 alveolar soft-part sarcoma 12.2
9 endometrial stromal sarcoma 12.1
10 epithelioid sarcoma 12.1
11 langerhans cell sarcoma 12.1
12 soft tissue sarcoma 12.1
13 clear cell sarcoma 12.1
14 mast-cell sarcoma 12.1
15 sarcoma, synovial 12.1
16 undifferentiated pleomorphic sarcoma 12.1
17 histiocytic sarcoma 12.0
18 paraganglioma and gastric stromal sarcoma 12.0
19 spindle cell sarcoma 12.0
20 uterine sarcoma 12.0
21 prostate stromal sarcoma 12.0
22 retroperitoneal sarcoma 11.9
23 bladder sarcoma 11.9
24 heart sarcoma 11.9
25 liver sarcoma 11.9
26 esophagus sarcoma 11.9
27 interdigitating dendritic cell sarcoma 11.9
28 reticulum cell sarcoma 11.9
29 gallbladder sarcoma 11.9
30 kidney clear cell sarcoma 11.9
31 bone ewing's sarcoma 11.8
32 mediastinum synovial sarcoma 11.8
33 rectum kaposi's sarcoma 11.8
34 small intestinal sarcoma 11.8
35 rectum sarcoma 11.8
36 extraosseous ewing's sarcoma 11.8
37 vulvar alveolar soft part sarcoma 11.8
38 bile duct sarcoma 11.8
39 anus sarcoma 11.8
40 kidney osteogenic sarcoma 11.8
41 colon kaposi sarcoma 11.8
42 paranasal sinus sarcoma 11.8
43 mediastinum sarcoma 11.8
44 penis sarcoma 11.8
45 trachea sarcoma 11.8
46 testis sarcoma 11.8
47 biphasic synovial sarcoma 11.8
48 kidney sarcoma 11.8
49 undifferentiated embryonal sarcoma of the liver 11.8
50 monophasic synovial sarcoma 11.8

Graphical network of the top 20 diseases related to Sarcoma:



Diseases related to Sarcoma

Symptoms & Phenotypes for Sarcoma

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.07 BRAF KRAS
2 Decreased viability GR00106-A-0 10.07 KRAS
3 Decreased viability GR00221-A-1 10.07 KIT KRAS
4 Decreased viability GR00221-A-2 10.07 KRAS
5 Decreased viability GR00221-A-4 10.07 BRAF
6 Decreased viability GR00301-A 10.07 BRAF KIT KRAS SRC
7 Decreased viability GR00381-A-1 10.07 BRAF KRAS
8 Decreased substrate adherent cell growth GR00193-A-1 9.92 KIT
9 Decreased substrate adherent cell growth GR00193-A-2 9.92 YES1 KIT
10 Decreased substrate adherent cell growth GR00193-A-3 9.92 YES1 BRAF
11 Decreased substrate adherent cell growth GR00193-A-4 9.92 KIT YES1 BRAF
12 Decreased cell migration GR00055-A-1 9.85 YES1 BRAF FES HRAS KRAS LYN
13 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.81 SSX2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.81 BRAF
15 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.81 SSX1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.81 BRAF SSX1 SSX2 SSX3 SSX5
17 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.81 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.81 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.81 BRAF
20 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.81 SSX3 SSX5
21 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.81 SSX1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.81 BRAF
23 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.81 SSX2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.81 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.81 BRAF
26 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.81 BRAF SSX3
27 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.81 SSX5
28 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.81 SSX5
29 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.81 SSX1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.81 SSX1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.81 SSX5
32 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.81 SSX2 SSX3
33 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.81 SSX3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.81 SSX2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.81 SSX5
36 Increased shRNA abundance (Z-score > 2) GR00366-A-92 9.81 SSX3
37 Decreased viability in HMC1.1 cells GR00105-A-0 9.33 KIT LYN SRC
38 Increased cell migration GR00055-A-3 9.26 LYN BRAF HRAS KRAS

MGI Mouse Phenotypes related to Sarcoma:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.26 BRAF CREB3L2 FES FLI1 HRAS JUN
2 mortality/aging MP:0010768 10.22 RB1 SRC SS18 YES1 CREB3L2 FES
3 integument MP:0010771 10.16 BRAF FES HRAS JUN KIT KRAS
4 endocrine/exocrine gland MP:0005379 10.15 JUN KIT KRAS RB1 SRC BRAF
5 craniofacial MP:0005382 10.13 BRAF CREB3L2 FES HRAS KIT KRAS
6 embryo MP:0005380 10.11 BRAF FLI1 JUN KIT KRAS RB1
7 nervous system MP:0003631 10.1 FES FLI1 HRAS JUN KIT KRAS
8 liver/biliary system MP:0005370 10.03 BRAF FES FLI1 JUN KIT KRAS
9 neoplasm MP:0002006 9.97 BRAF FES FLI1 HRAS KIT KRAS
10 renal/urinary system MP:0005367 9.7 BRAF HRAS KIT KRAS LYN RB1
11 pigmentation MP:0001186 9.65 BRAF KIT KRAS RB1 SRC
12 respiratory system MP:0005388 9.61 YES1 BRAF HRAS JUN KIT KRAS
13 skeleton MP:0005390 9.28 BRAF CREB3L2 HRAS JUN KIT KRAS

Drugs & Therapeutics for Sarcoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Doxil 17 46 DOXORUBICIN HYDROCHLORIDE Alza June 1999
2
Fusilev 17 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
3
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
4
Taxol 17 46 PACLITAXEL Bristol-Myers Squibb August 1997
5
Votrient 17 46 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 592)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
5
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
6
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
7
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
8
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
9
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
10
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
11
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
12
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
13
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
14
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 1 154361-50-9 60953
15
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
16
Dalteparin Approved Phase 4,Phase 1 9005-49-6
17
Heparin Approved, Investigational Phase 4,Phase 1 9005-49-6 772 46507594
18
Ethiodized oil Approved Phase 4 8008-53-5
19
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
20 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
26 Vaccines Phase 4,Phase 1,Phase 2
27 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
30 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
36 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
37 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
38 Antibodies Phase 4,Phase 3,Phase 1,Phase 2
39 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2
40 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2
41 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
42 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
45 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
48 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
49 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
50 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 1644)

id Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
4 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
5 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
6 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
7 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
8 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
9 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
10 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
11 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Not yet recruiting NCT03144206 Phase 4 Hyperbaric oxygen
12 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Not yet recruiting NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
13 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Not yet recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
14 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
15 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
16 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
17 An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial Unknown status NCT00384735 Phase 3
18 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
19 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
20 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
21 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
22 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
23 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3 imatinib mesylate
24 Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor Unknown status NCT00103168 Phase 3 imatinib mesylate
25 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
26 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
27 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
28 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
29 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
30 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
31 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
32 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
33 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
34 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
35 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
36 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
37 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
38 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
39 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
40 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
41 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
42 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
43 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
44 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
45 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
46 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3 IM862
47 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3 doxorubicin;ifosfamide;mesna
48 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
49 Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy Completed NCT00283582 Phase 3 rhTPO
50 A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Sarcoma

Genetic tests related to Sarcoma:

id Genetic test Affiliating Genes
1 Sarcoma 29

Anatomical Context for Sarcoma

MalaCards organs/tissues related to Sarcoma:

39
Bone, Myeloid, Lung, Kidney, Liver, Uterus, T Cells

Publications for Sarcoma

Articles related to Sarcoma:

(show top 50) (show all 9301)
id Title Authors Year
1
Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. ( 28633614 )
2018
2
Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma. ( 28288693 )
2017
3
Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy. ( 28621004 )
2017
4
The importance of treating by histological subtype in advanced soft tissue sarcoma. ( 27918201 )
2017
5
Kaposi's Sarcoma-Associated Herpesvirus MicroRNAs Target GADD45B To Protect Infected Cells from Cell Cycle Arrest and Apoptosis. ( 27852859 )
2017
6
Appendix 3: Soft tissue sarcoma: MCBS eUpdate published online 5 May 2017(www.esmo.org/Guidelines/Sarcoma-and-GIST). ( 28881924 )
2017
7
Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. ( 28739691 )
2017
8
Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden. ( 28662221 )
2017
9
Monophasic synovial sarcoma of the greater omentum: case report and review of literature. ( 28660813 )
2017
10
Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. ( 28806574 )
2017
11
Follicular Dendritic Cell Sarcoma. ( 28353378 )
2017
12
Microscopic Infiltration of Cryopreserved Ovarian Tissue in 2 Patients With Ewing Sarcoma. ( 28816797 )
2017
13
Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma. ( 28451803 )
2017
14
Kaposi Sarcoma and Lung Transplant: Two Case Reports. ( 28501344 )
2017
15
Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays. ( 28045549 )
2017
16
Oral Kaposi Sarcoma in HIV-seronegative Saudi patient: Literature review and case report. ( 28725131 )
2017
17
A case of clear cell sarcoma-A rare malignancy. ( 28587971 )
2017
18
Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics. ( 28805986 )
2017
19
Spindle-cell sarcoma involving the major pulmonary arteries. ( 28670068 )
2017
20
Extra-skeletal Ewing sarcoma of the lumbosacral region in an adult pregnant patient: a case report. ( 28435928 )
2017
21
Inadvertently boarding a pirate ship: disease progression in a paediatric patient with relapsed metastatic Ewing sarcoma receiving treatment at a centre for alternative therapy in Mexico. ( 28062429 )
2017
22
Discussing sarcoma risks during informed consent for non-hysterectomy management of fibroids: An unmet need. ( 28951264 )
2017
23
Is acquired arterial-venous fistula related to Kaposi sarcoma? ( 28214029 )
2017
24
A Rare Case of Malignant Fibrous Histiocytoma (Undifferentiated High-Grade Pleomorphic Sarcoma) of Malar Region. ( 28468216 )
2017
25
Improved local control with an aggressive strategy of preoperative (with or without intraoperative) radiation therapy combined with radical surgical resection for retroperitoneal sarcoma. ( 28127762 )
2017
26
BRAF (V600E) expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report. ( 28376906 )
2017
27
Myositis ossificans in elbow mimicking soft tissue sarcoma: Similar clinical and radiological findings. ( 28641932 )
2017
28
Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2. ( 28833247 )
2017
29
Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. ( 27993576 )
2017
30
Surgical management of pelvic bone sarcoma with internal hemipelvectomy: Oncologic and Functional outcomes. ( 28951642 )
2017
31
Magnetic resonance imaging features of endometrial stromal sarcoma: a case description. ( 28275572 )
2017
32
Does the patients age at cancer diagnosis affect microvessels density in uterine sarcoma tissues? ( 28397202 )
2017
33
Bladder Recurrence of Clear Cell Sarcoma of the Kidney Seven Years After Initial Presentation. ( 28438624 )
2017
34
Ewing sarcoma of the sternal manubrium: first report of a case in Australasia and review of the literature. ( 28419662 )
2017
35
Histone 3.3 Mutations in Giant Cell Tumor and Giant Cell-Rich Sarcomas of Bone. ( 28899740 )
2017
36
Bone Marrow Involvement in Metastatic Pediatric Ewing Sarcoma. ( 28903844 )
2017
37
Comparison of Kaposi sarcoma risk in HIV-positive adults across five continents: a multiregional multicohort study. ( 28531260 )
2017
38
No detectable human herpesvirus-8 oral shedding in seronegative-healthy, immunocompetent individuals from non-endemic regions for Kaposi's sarcoma: A pilot study. ( 28631891 )
2017
39
Myeloid sarcoma causing airway obstruction. ( 28405080 )
2017
40
Uterine sarcoma - current perspectives. ( 28919822 )
2017
41
Alveolar soft part sarcoma: A case report with emphasis on some unusual cytological features. ( 28905497 )
2017
42
Aggressively progressing primary undifferentiated pleomorphic sarcoma in the eyelid: A case report and review of the literature. ( 28471957 )
2017
43
Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013. ( 28829790 )
2017
44
Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. ( 28145886 )
2017
45
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. AA retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression FranAsaise (ANOCEF). ( 28478340 )
2017
46
PAX8-positive Biphasic Synovial Sarcoma Expressing Hormonal Receptors. ( 28248726 )
2017
47
Predictors of surgical quality for retroperitoneal sarcoma: Volume matters. ( 28608360 )
2017
48
18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma. ( 28186981 )
2017
49
Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma. ( 28816792 )
2017
50
Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma. ( 28060130 )
2017

Variations for Sarcoma

ClinVar genetic disease variations for Sarcoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
2 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091

Expression for Sarcoma

Search GEO for disease gene expression data for Sarcoma.

Pathways for Sarcoma

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 96)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 BRAF FES HRAS JUN KIT KRAS
2
Show member pathways
13.43 BRAF HRAS KIT KRAS LYN SRC
3
Show member pathways
13.29 BRAF FES HRAS JUN KRAS LYN
4
Show member pathways
13.13 BRAF HRAS KIT KRAS LYN SRC
5
Show member pathways
12.97 BRAF HRAS JUN KRAS RB1 SRC
6
Show member pathways
12.96 BRAF CREB3L2 HRAS JUN KRAS SRC
7
Show member pathways
12.95 BRAF HRAS JUN KRAS LYN SRC
8
Show member pathways
12.9 BRAF CREB3L2 HRAS KRAS SRC YES1
9
Show member pathways
12.86 BRAF HRAS JUN KRAS SRC
10
Show member pathways
12.86 BRAF HRAS JUN KRAS SRC
11
Show member pathways
12.85 BRAF HRAS JUN KIT KRAS LYN
12
Show member pathways
12.8 BRAF HRAS KIT KRAS SRC
13
Show member pathways
12.8 HRAS KIT KRAS LYN SRC
14
Show member pathways
12.74 BRAF HRAS JUN KRAS RB1
15 12.74 BRAF HRAS JUN KIT KRAS RB1
16
Show member pathways
12.66 HRAS JUN KRAS LYN SRC
17
Show member pathways
12.61 BRAF CREB3L2 HRAS JUN KIT KRAS
18
Show member pathways
12.59 BRAF HRAS JUN KRAS SRC
19
Show member pathways
12.48 HRAS KRAS LYN SRC
20 12.48 HRAS JUN KRAS RB1
21
Show member pathways
12.48 HRAS KRAS RB1 SRC
22
Show member pathways
12.46 BRAF HRAS KRAS SRC
23
Show member pathways
12.46 HRAS JUN KIT KRAS
24
Show member pathways
12.46 BRAF HRAS JUN KRAS LYN
25
Show member pathways
12.43 BRAF HRAS JUN SRC
26
Show member pathways
12.43 CREB3L2 HRAS KIT KRAS SRC
27
Show member pathways
12.42 HRAS JUN KRAS SRC
28
Show member pathways
12.41 BRAF HRAS JUN KRAS LYN SRC
29
Show member pathways
12.4 BRAF HRAS JUN KRAS
30
Show member pathways
12.39 CREB3L2 HRAS JUN KRAS LYN
31
Show member pathways
12.38 BRAF HRAS JUN KRAS SRC
32 12.37 BRAF HRAS KRAS SRC
33
Show member pathways
12.36 BRAF HRAS KRAS SRC
34
Show member pathways
12.36 BRAF HRAS JUN KRAS SRC YES1
35
Show member pathways
12.35 HRAS KRAS SRC YES1
36
Show member pathways
12.34 BRAF HRAS KRAS SRC
37
Show member pathways
12.31 BRAF HRAS JUN SRC YES1
38
Show member pathways
12.3 HRAS KRAS LYN SRC YES1
39 12.29 FES HRAS KRAS SRC
40
Show member pathways
12.27 HRAS JUN KRAS SRC
41
Show member pathways
12.27 BRAF HRAS KRAS SRC
42
Show member pathways
12.26 BRAF CREB3L2 HRAS KRAS RB1 SRC
43 12.25 BRAF HRAS JUN KRAS SRC
44
Show member pathways
12.24 BRAF HRAS JUN KRAS
45
Show member pathways
12.24 BRAF HRAS JUN KRAS SRC
46
Show member pathways
12.23 HRAS JUN KIT LYN SRC
47
Show member pathways
12.21 BRAF HRAS JUN KRAS
48
Show member pathways
12.21 HRAS JUN KRAS SRC
49 12.19 BRAF FAU JUN KRAS RB1
50 12.17 ASPSCR1 EWSR1 FLI1 SS18 SSX1 SSX2

GO Terms for Sarcoma

Cellular components related to Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.83 ASPSCR1 BRAF CREB3L2 EWSR1 FLI1 HRAS
2 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 9.02 FES KRAS LYN SRC YES1

Biological processes related to Sarcoma according to GeneCards Suite gene sharing:

(show all 33)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 BRAF HRAS KIT KRAS SRC
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 BRAF HRAS JUN SRC
3 Fc-epsilon receptor signaling pathway GO:0038095 9.9 HRAS JUN KRAS LYN
4 leukocyte migration GO:0050900 9.88 HRAS KRAS LYN SRC YES1
5 negative regulation of neuron apoptotic process GO:0043524 9.84 BRAF HRAS JUN KRAS
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 LYN SRC YES1
7 protein autophosphorylation GO:0046777 9.83 FES KIT LYN SRC YES1
8 T cell costimulation GO:0031295 9.82 LYN SRC YES1
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.81 HRAS KRAS LYN SRC
10 peptidyl-tyrosine phosphorylation GO:0018108 9.8 FES KIT LYN SRC YES1
11 Ras protein signal transduction GO:0007265 9.76 HRAS JUN KRAS RB1
12 visual learning GO:0008542 9.73 BRAF KIT KRAS
13 ERBB2 signaling pathway GO:0038128 9.7 HRAS KRAS SRC
14 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.67 KIT LYN SRC
15 positive regulation of MAP kinase activity GO:0043406 9.67 HRAS KIT KRAS SRC
16 striated muscle cell differentiation GO:0051146 9.65 KRAS RB1
17 regulation of vascular permeability GO:0043114 9.64 SRC YES1
18 regulation of mast cell degranulation GO:0043304 9.63 FES LYN
19 response to isolation stress GO:0035900 9.63 HRAS KRAS
20 epidermal growth factor receptor signaling pathway GO:0007173 9.62 FES HRAS KRAS SRC
21 myeloid progenitor cell differentiation GO:0002318 9.58 BRAF KIT
22 negative regulation of nucleic acid-templated transcription GO:1903507 9.56 SSX1 SSX2 SSX3 SSX5
23 response to mineralocorticoid GO:0051385 9.55 KRAS SRC
24 peptidyl-tyrosine autophosphorylation GO:0038083 9.46 FES LYN SRC YES1
25 regulation of cell proliferation GO:0042127 9.43 BRAF FES JUN KIT SRC YES1
26 ephrin receptor signaling pathway GO:0048013 9.02 HRAS LYN SRC SS18 YES1
27 regulation of transcription, DNA-templated GO:0006355 10.3 CREB3L2 EWSR1 FLI1 JUN RB1 SS18
28 transcription, DNA-templated GO:0006351 10.27 CREB3L2 EWSR1 FLI1 JUN RB1 SS18
29 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.16 CREB3L2 FLI1 HRAS JUN RB1 SS18
30 phosphorylation GO:0016310 10.09 BRAF FES KIT LYN SRC YES1
31 positive regulation of cell proliferation GO:0008284 10.06 HRAS JUN KIT KRAS LYN
32 protein phosphorylation GO:0006468 10.05 BRAF FES KIT LYN SRC YES1
33 intracellular signal transduction GO:0035556 10.04 BRAF KIT LYN SRC SS18

Molecular functions related to Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.88 BRAF FES KIT LYN SRC YES1
2 enzyme binding GO:0019899 9.77 JUN LYN RB1 SRC YES1
3 transcription corepressor activity GO:0003714 9.73 SSX1 SSX2 SSX3 SSX5
4 protein kinase activity GO:0004672 9.73 BRAF FES KIT LYN SRC YES1
5 phosphoprotein binding GO:0051219 9.5 LYN RB1 SRC
6 cAMP response element binding GO:0035497 9.48 CREB3L2 JUN
7 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.46 KIT LYN
8 protein tyrosine kinase activity GO:0004713 9.35 FES KIT LYN SRC YES1
9 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.92 FES LYN SRC YES1
10 protein binding GO:0005515 10.11 ASPSCR1 BRAF EWSR1 FES FLI1 HRAS

Sources for Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....